850 related articles for article (PubMed ID: 33679726)
1. Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer.
Bödder J; Zahan T; van Slooten R; Schreibelt G; de Vries IJM; Flórez-Grau G
Front Immunol; 2020; 11():631713. PubMed ID: 33679726
[TBL] [Abstract][Full Text] [Related]
2. The Natural Killer-Dendritic Cell Immune Axis in Anti-Cancer Immunity and Immunotherapy.
Peterson EE; Barry KC
Front Immunol; 2020; 11():621254. PubMed ID: 33613552
[TBL] [Abstract][Full Text] [Related]
3. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.
Fu C; Jiang A
Front Immunol; 2018; 9():3059. PubMed ID: 30619378
[TBL] [Abstract][Full Text] [Related]
4. Natural killer-dendritic cell cross-talk in cancer immunotherapy.
Kalinski P; Mailliard RB; Giermasz A; Zeh HJ; Basse P; Bartlett DL; Kirkwood JM; Lotze MT; Herberman RB
Expert Opin Biol Ther; 2005 Oct; 5(10):1303-15. PubMed ID: 16197336
[TBL] [Abstract][Full Text] [Related]
5. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
Gaggero S; Witt K; Carlsten M; Mitra S
Front Immunol; 2020; 11():621225. PubMed ID: 33584718
[TBL] [Abstract][Full Text] [Related]
6. NK Cell Anti-Tumor Surveillance in a Myeloid Cell-Shaped Environment.
Russo E; Laffranchi M; Tomaipitinca L; Del Prete A; Santoni A; Sozzani S; Bernardini G
Front Immunol; 2021; 12():787116. PubMed ID: 34975880
[TBL] [Abstract][Full Text] [Related]
7. Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity.
Noubade R; Majri-Morrison S; Tarbell KV
Front Immunol; 2019; 10():1014. PubMed ID: 31143179
[TBL] [Abstract][Full Text] [Related]
8. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
9. The interaction of NK cells and dendritic cells in the tumor environment: how to enforce NK cell & DC action under immunosuppressive conditions?
Jacobs B; Ullrich E
Curr Med Chem; 2012; 19(12):1771-9. PubMed ID: 22414086
[TBL] [Abstract][Full Text] [Related]
10. Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens.
Tosi D; Valenti R; Cova A; Sovena G; Huber V; Pilla L; Arienti F; Belardelli F; Parmiani G; Rivoltini L
J Immunol; 2004 May; 172(9):5363-70. PubMed ID: 15100276
[TBL] [Abstract][Full Text] [Related]
11. Characterization and Manipulation of the Crosstalk Between Dendritic and Natural Killer Cells Within the Tumor Microenvironment.
Jacobs B; Gebel V; Heger L; Grèze V; Schild H; Dudziak D; Ullrich E
Front Immunol; 2021; 12():670540. PubMed ID: 34054844
[TBL] [Abstract][Full Text] [Related]
12. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel JC; Crozat K; Dalod M; Mattiuz R
Front Immunol; 2019; 10():9. PubMed ID: 30809220
[TBL] [Abstract][Full Text] [Related]
13. Modification of anti-tumor immunity by tolerogenic dendritic cells.
Chen L; Hasni MS; Jondal M; Yakimchuk K
Autoimmunity; 2017 Sep; 50(6):370-376. PubMed ID: 28675711
[TBL] [Abstract][Full Text] [Related]
14. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
15. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
Front Immunol; 2018; 9():2905. PubMed ID: 30619269
[TBL] [Abstract][Full Text] [Related]
16. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
Carnevalli LS; Ghadially H; Barry ST
Front Immunol; 2021; 12():633685. PubMed ID: 33953710
[TBL] [Abstract][Full Text] [Related]
18. Clinically applicable CD34
van Eck van der Sluijs J; van Ens D; Thordardottir S; Vodegel D; Hermens I; van der Waart AB; Falkenburg JHF; Kester MGD; de Rink I; Heemskerk MHM; Borst J; Schaap NPM; Jansen JH; Xiao Y; Dolstra H; Hobo W
Cancer Immunol Immunother; 2021 Nov; 70(11):3167-3181. PubMed ID: 33796917
[TBL] [Abstract][Full Text] [Related]
19. Harnessing dendritic cells in cancer.
Apetoh L; Locher C; Ghiringhelli F; Kroemer G; Zitvogel L
Semin Immunol; 2011 Feb; 23(1):42-9. PubMed ID: 21295491
[TBL] [Abstract][Full Text] [Related]
20. NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge.
Bouwer AL; Saunderson SC; Caldwell FJ; Damani TT; Pelham SJ; Dunn AC; Jack RW; Stoitzner P; McLellan AD
J Immunol; 2014 Mar; 192(5):2514-21. PubMed ID: 24477907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
